AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses the results of a trial that examined AR-V7 and resistance to enzalutamide and abiraterone in patients with prostate cancer.

Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses the results of a trial that examined AR-V7 and resistance to enzalutamide and abiraterone in patients with prostate cancer.

Clinical Pearls

  • The study showed that about 39% (12 of 31) of patients in the enzalutamide arm had AR-V7 detected in their circulating tumor cells.
  • Every patient taking enzalutamide that had AR-V7 did not obtain a PSA response to enzalutamide.
  • In the abiraterone arm, 19% (6 of 31) were found to have AR-V7.
  • Similarly, all of these patients demonstrated resistance to abiraterone. ​

<<<

View more from the 2014 ESMO Congress